Download PDF
Digestive Disease Interventions 2021; 05(01): 050-054
DOI: 10.1055/s-0040-1722267
Review Article

Intratumoral and Oncoviral Immunotherapy

Rahul A. Sheth
1   Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Immunotherapy is a paradigm-shifting advance in cancer care, but despite their success, contemporary immunotherapy strategies are limited by several factors. The objective response rates to checkpoint inhibitor therapy remain below 50%, and the toxicities associated with systemically administered immunotherapies, particularly combination immunotherapy regimens, can be devastating. Intratumoral immunotherapies represent a burgeoning paradigm in immuno-oncology designed to address these limitations. The direct delivery of intratumoral immunotherapies can result in concentrations of the therapeutic agent at levels that would likely be far too toxic if administered systemically. In this review, I summarize the sound biological framework underlying intratumoral immunotherapies as well as provide an overview of the major categories of intratumoral agents currently under investigation. I also emphasize the components of this treatment strategy that are relevant for image-guided interventionalists based on existing clinical experience.

Keywords

immunotherapy - image guided interventions - interventional oncology - oncolytic therapy


Publication History

Received: 01 July 2020

Accepted: 25 November 2020

Article published online:
19 January 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015; 161 (02) 205-214
    CrossrefPubMedGoogle Scholar
  • 2 Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348 (6230): 56-61
    CrossrefPubMedGoogle Scholar
  • 3 Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 2017; 377 (25) 2500-2501
    CrossrefPubMedGoogle Scholar
  • 4 Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378 (02) 158-168
    CrossrefPubMedGoogle Scholar
  • 5 Marabelle A, Tselikas L, de Baere T, Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol 2017; 28 (Suppl. 12) xii33-xii43
    CrossrefPubMedGoogle Scholar
  • 6 Galluzzi L, Vitale I, Warren S. et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer 2020; 8 (01) e000337
    CrossrefPubMedGoogle Scholar
  • 7 Andtbacka RHI, Kaufman HL, Collichio F. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33 (25) 2780-2788
    CrossrefPubMedGoogle Scholar
  • 8 Andtbacka RHI, Ross M, Puzanov I. et al. Patterns of clinical response with Talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol 2016; 23 (13) 4169-4177
    CrossrefPubMedGoogle Scholar
  • 9 Louie RJ, Perez MC, Jajja MR. et al. Real-world outcomes of Talimogene laherparepvec therapy: a multi-institutional experience. J Am Coll Surg 2019; 228 (04) 644-649
    CrossrefPubMedGoogle Scholar
  • 10 Ribas A, Dummer R, Puzanov I. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 2017; 170 (06) 1109-1119.e10
    CrossrefPubMedGoogle Scholar
  • 11 Hecht JR, Pless M, Cubillo A. et al. Early safety from a phase I, multicenter, open-label clinical trial of Talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem). J Clin Oncol 2020; 38: 3015
    CrossrefPubMedGoogle Scholar
  • 12 Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015; 14 (09) 642-662
    CrossrefPubMedGoogle Scholar
  • 13 Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer 2018; 18 (07) 419-432
    CrossrefPubMedGoogle Scholar
  • 14 Russell SJ, Barber GN. Oncolytic viruses as antigen-agnostic cancer vaccines. Cancer Cell 2018; 33 (04) 599-605
    CrossrefPubMedGoogle Scholar
  • 15 Aznar MA, Tinari N, Rullán AJ, Sánchez-Paulete AR, Rodriguez-Ruiz ME, Melero I. Intratumoral delivery of immunotherapy-act locally, think globally. J Immunol 2017; 198 (01) 31-39
    CrossrefPubMedGoogle Scholar
  • 16 Sheth RA, Hesketh R, Kong DS, Wicky S, Oklu R. Barriers to drug delivery in interventional oncology. J Vasc Interv Radiol 2013; 24 (08) 1201-1207
    CrossrefPubMedGoogle Scholar
  • 17 Bhatia S, Miller NJ, Lu H. et al. Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in patients with merkel cell carcinoma. Clin Cancer Res 2019; 25 (04) 1185-1195
    CrossrefPubMedGoogle Scholar
  • 18 Brody JD, Ai WZ, Czerwinski DK. et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010; 28 (28) 4324-4332
    CrossrefPubMedGoogle Scholar
  • 19 Frank MJ, Reagan PM, Bartlett NL. et al. In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma. Cancer Discov 2018; 8 (10) 1258-1269
    CrossrefPubMedGoogle Scholar
  • 20 Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol 2015; 15 (12) 760-770
    CrossrefPubMedGoogle Scholar
  • 21 Meric-Bernstam F, Sandhu SK, Hamid O. et al. Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. J Clin Oncol 2019; 37: 2507
    CrossrefPubMedGoogle Scholar
  • 22 Sheth RA, Murthy R, Hong DS. et al. Assessment of image-guided intratumoral delivery of immunotherapeutics in patients with cancer. JAMA Netw Open 2020; 3 (07) e207911
    CrossrefPubMedGoogle Scholar